Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:45 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
NCT01953926 · Puma Biotechnology, Inc. · PHASE2 · terminated · last registry update 2024-03-12 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated to align with the sponsor's current development plans for neratinib. The decision was not based on any new efficacy or safety data for neratinib.” | – | Registry record, Puma Biotechnology, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGFR in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-16Phase 3 first posted: Prof. Wolfgang Janni, Trastuzumab-Deruxtecan (NCT06643585)
- 2024-05-22Results posted on the registry: Dana-Farber Cancer Institute, HKI-272 + Capecitabine (NCT01494662)
- 2024-03-15Phase 3 first posted: Tianjin Hemay Pharmaceutical Co., Ltd, Hemay022+AI + Lapatinib+Capecitabine (NCT06313983)
- 2023-11-18Results posted on the registry: University of California, San Francisco, Neratinib + Trastuzumab (NCT03094052)
- 2023-06-26Results posted on the registry: Daiichi Sankyo, Trastuzumab deruxtecan + Capecitabine (NCT03523585)
- 2023-03-21Results posted on the registry: Dana-Farber Cancer Institute, Neratinib + Fulvestrant (NCT03289039)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision